SWITCH-BLOCKER
LIVE

Serial Number

98853592

Owner

Aegea Biotechnologies, Inc.

Attorney

Barry F. Soalt

Filing Date

Nov 14, 2024

Add to watchlist:

No watchlists yet
View on USPTO

SWITCH-BLOCKER Trademark

Serial Number: 98853592

SWITCH-BLOCKER is a trademark filed by Aegea Biotechnologies, Inc. on November 14, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Aegea Biotechnologies, Inc. (2 trademarks)

15638 Boulder Mt. Road
Poway, CA 92064

Entity Type: 03

Trademark Details

Filing Date

November 14, 2024

Registration Date

Not Registered

Published for Opposition

November 4, 2025

Goods & Services

Health assessment services; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; and consulting services in the fields of diagnostic medical testing and treatment of diseases

Medical, scientific and clinical research in the fields of diagnostics, genomics, next generation sequencing (NGS) and therapeutics, molecular diagnostics for the detection of DNA and RNA targets of interest, Sanger sequencing, NGS, capillary electrophoresis, mass-spectral analysis, and microarray analysis

Medical diagnostic apparatus and instruments for testing DNA and RNA and for diagnostic testing for the interrogation of DNA and RNA nucleic acids for any disease or condition where it is desired to detect specific nucleic acids or derivative thereof, namely, cancer, an infectious disease, inherited genetic disease, somatic aberration, and rejection of transplanted organs

Medical diagnostic reagents and assays for testing of bodily fluids for use in detection of any disease or condition where it is desired to detect specific nucleic acids or derivatives thereof, namely, cancer, infectious disease, inherited genetic disease, somatic aberration, and rejection of transplanted organs; drug testing kits comprised of medical diagnostic reagents and assays that test for the presence of gene events, namely, mutations, single nucleotide polymorphisms (SNP's) and other disease biomarkers, translocations, deletions, gene copy number changes, RNA expression levels, and biomarkers specific to disease conditions; drug testing kits comprised of medical diagnostic reagents and assays, test strips, test patches, and test media for testing of bodily fluids for use in detection of any disease or condition where it is desired to detect specific nucleic acids or derivatives thereof, namely, cancer, infectious disease, inherited genetic disease, somatic aberration, and rejection of transplanted organs

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 29, 2026 EXRA
SOU EXTENSION 1 GRANTED
Apr 28, 2026 EX1G
SOU EXTENSION 1 FILED
Apr 28, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 28, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 30, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 4, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 4, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 29, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 6, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 6, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 6, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 6, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 6, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 13, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 13, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 13, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 16, 2025 GNRN
NON-FINAL ACTION E-MAILED
May 16, 2025 GNRT
NON-FINAL ACTION WRITTEN
May 16, 2025 CNRT
ASSIGNED TO EXAMINER
May 9, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 8, 2025 NWOS
NEW APPLICATION ENTERED
Nov 14, 2024 NWAP